Sorrento Provides Positive Update for COVIDTRAP
Sorrento Therapeutics Inc. (SRNE) announced completing the preclinical batch of COVIDTRAP protein. The company reported that it has obtained positive results from preclinical testing of the drug candidate STI-4398. Sorrento plans to develop the candidate on two different fronts which are as a treatment and as a preventive therapy for COVID-19. The company is working on multiple drug candidates for treating coronavirus.
COVIDTRAP or STI-4398 is a protein that has shown the potential to neutralize the SARS-CoV-2 virus. The company claimed that the drug candidate inhibited the